{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:24:09Z","timestamp":1761895449043},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,3,30]],"date-time":"2012-03-30T00:00:00Z","timestamp":1333065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s12185-012-1043-8","type":"journal-article","created":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T06:23:01Z","timestamp":1333002181000},"page":"535-544","source":"Crossref","is-referenced-by-count":9,"title":["Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study"],"prefix":"10.1007","volume":"95","author":[{"given":"Peter C.","family":"Trask","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debanjali","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrividya","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean D.","family":"Candrilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,30]]},"reference":[{"key":"1043_CR1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocyic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"1043_CR2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"1043_CR3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Drucker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054\u201361.","journal-title":"Leukemia"},{"key":"1043_CR4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"1043_CR5","doi-asserted-by":"crossref","unstructured":"Mauro MJ, Baccarani M, Cervantes F, Lipton JH, Matloub Y, Sinha R et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol. 2008; 26(May 20 suppl) (Abstract No. 7009).","DOI":"10.1200\/jco.2008.26.15_suppl.7009"},{"key":"1043_CR6","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, Tanaka C, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542\u201351.","journal-title":"N Engl J Med"},{"key":"1043_CR7","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Giles FG, Bhalla J, Pinilla R, Larson N, Gattermann O et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: Longer follow-up results of a phase 2 study. Haematologica. 2009;94(suppl 2):254 (Abstract No. 0627).","DOI":"10.1182\/blood.V112.11.3238.3238"},{"key":"1043_CR8","first-page":"49","volume":"25","author":"JE Sokal","year":"1988","unstructured":"Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49\u201361.","journal-title":"Semin Hematol"},{"key":"1043_CR9","doi-asserted-by":"crossref","unstructured":"Deininger M. Milestones and monitoring in patients with CML treated with imatinib. Hematology. American Society of Hematology Education Program Book 2008;\u00a0419\u201326.","DOI":"10.1182\/asheducation-2008.1.419"},{"key":"1043_CR10","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade De","year":"2008","unstructured":"De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention to treat analysis. J Clin Oncol. 2008;26:3358\u201363.","journal-title":"J Clin Oncol"},{"key":"1043_CR11","doi-asserted-by":"crossref","unstructured":"Foryciarz K, Sacha T, Florek I, Czekalska S, Zawada M, Skotnicki AB. Prognostic factors in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors\u2014single center experience. ASH Annual Meeting Abstracts. Blood. 2009; 114(22) (Abstract No. 2210).","DOI":"10.1182\/blood.V114.22.2210.2210"},{"issue":"11","key":"1043_CR12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1043_CR13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373\u201383.","journal-title":"J Chron Dis."},{"key":"1043_CR14","unstructured":"CIA World Factbook. https:\/\/www.cia.gov\/library\/publications\/the-world-factbook\/geos\/ja.html . Accessed 18 Aug 2011."},{"key":"1043_CR15","doi-asserted-by":"crossref","unstructured":"Baccarani M, Dreyling M; on behalf of the ESMO Guidelines Working Group. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl5):v165\u20137.","DOI":"10.1093\/annonc\/mdq201"},{"key":"1043_CR16","unstructured":"NCCN Guidelines. Version 2.2012. Chronic myelogenous leukemia. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf . Accessed 24 Aug 2011."},{"key":"1043_CR17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, Henk HJ, Thomas SK, Feng W, Baladi J-F, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs. Pharmacoeconomics. 2007;25:481\u201396.","journal-title":"Pharmacoeconomics."},{"key":"1043_CR18","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.2010.33.4169","volume":"29","author":"H Kantarjian","year":"2011","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, et al. Impact of treatment endpoint definitions on perceived differences in long-term outcomes with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011;29:3173\u20138.","journal-title":"J Clin Oncol"},{"key":"1043_CR19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686\u201392.","journal-title":"Blood"},{"key":"1043_CR20","doi-asserted-by":"crossref","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","DOI":"10.1056\/NEJMoa062867"},{"issue":"2","key":"1043_CR21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.kjms.2010.09.001","volume":"27","author":"HH Hsiao","year":"2001","unstructured":"Hsiao HH, Liu YC, Tsai HJ, Hsu JF, Yang WC, Chang CS, et al. Additional chromosome abnormalities in chronic myeloid leukemia. Kaohsiung J Med Sci. 2001;27(2):49\u201354.","journal-title":"Kaohsiung J Med Sci"},{"key":"1043_CR22","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Jabbour E, Giles FJ, Bhalla, KN, Pinilla-Ibarz J, Larson RA, et al. Prognostic factors for progression-free survival in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24\u00a0month data. Blood. 2009;114 (Abstract No. 3298).","DOI":"10.1182\/blood.V114.22.3298.3298"},{"key":"1043_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2010.32.2701","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sj\u00f6berg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:1\u20137.","journal-title":"J Clin Oncol"},{"key":"1043_CR24","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011;117:5591\u20139.","journal-title":"Blood"},{"key":"1043_CR25","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","volume":"26","author":"EQ Wu","year":"2010","unstructured":"Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26:2861\u20139.","journal-title":"Curr Med Res Opin"},{"key":"1043_CR26","doi-asserted-by":"crossref","unstructured":"Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012;95(3):263\u2013273.","DOI":"10.1007\/s12185-012-1010-4"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1043-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1043-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T01:08:16Z","timestamp":1593911296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1043-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,30]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1043"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1043-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,30]]}}}